Drug Database
UR

urokinase (Breokinase / Alphakinase / Thrombolase)

✓ Approved

Mitsubishi Tanabe Pharma Corporation · PLAU

What is urokinase?

urokinase is a therapeutic agent developed by Mitsubishi Tanabe Pharma Corporation. It is approved for therapeutic indications.

Drug Profile

Brand NamesBreokinase, Alphakinase, Thrombolase
CompanyMitsubishi Tanabe Pharma Corporation
Molecular TargetPLAU
StatusApproved

Mechanism of Action

Molecular Targets

urokinase acts on 1 molecular target:

PLAUplasminogen activator, urokinase (URK, UPA)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

urokinase is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Respiratory, thoracic and mediastinal disordersPulmonary thrombosis✓ Approved

Related Research Articles

PubMedFrontiers in immunology2026-09-18

Decreased expression of immune activator WARS1 and other pro-inflammatory mediators in type 1-like macrophages as an associated mode of action in response to fucoidan from marine brown algae.

Ostermann Jasmin J, Gemoll Timo T, Schnüttgen Tabea T, Tischhöfer Marie-Theres MT et al.

Macrophages are key regulators of innate and adaptive immune responses through antigen presentation and the production of inflammatory mediators and growth factors. Imbalances in the activation and inhibition of pro-inflammatory type 1-like macrophages (M1) and anti-inflammatory type 2-like macrophages (M2) are closely associated with various autoimmune and chronic inflammatory diseases, underscoring the need for targeted therapeutic approaches. Numerous studies have shown that sulfated polysaccharides from marine algae, especially fucoidans from brown algae, exhibit a wide range of anti-inflammatory activities. This study aims to investigate the anti-inflammatory mode of action of algae-derived fucoidans in monocyte-derived macrophages and to identify the key regulatory proteins and inflammatory mediators involved. We applied data-independent mass spectrometry to comprehensively evaluate protein profiles of monocyte-derived M1/M2-like macrophages under the influence of sulfated polysaccharides from different algae species, namely fucoidans from the brown algae Saccharina latissima, Fucus evanescens, and Laminaria digitata, as well as the sulfated xylogalactan from the red alga Delesseria sanguinea. Furthermore, a series of gradually depolymerized fractions of the fucoidan from Saccharina latissima was investigated to elucidate the impact of molecular weight (MW) on protein expression levels and cytokine secretion patterns using membrane-based cytokine arrays and ELISA measurements. Among the tested sulfated polysaccharides, especially the fucoidan from Saccharina latissima showed anti-inflammatory effects. They significantly reduced expression levels of pro-inflammatory tryptophanyl-tRNA synthetase (WARS1), the cytokines interferon gamma-induced protein 10 (IP-10, syn. CXCL10) and macrophage migration inhibitory factor (MIF), as well as urokinase-type plasminogen activator receptor (uPAR) in pro-inflammatory M1-like macrophages, whereby their effects turned out to be independent of the MW. Our study provides novel insights into the anti-inflammatory mode of action of fucoidan from Saccharina latissimima on monocyte-derived macrophages. Further in vitro and in vivo studies are required to better understand the underlying molecular pathways, the associated mechanism and to evaluate potential medical applications.

PubMedClinics (Sao Paulo, Brazil)2026-09-18

Comparison of the short-term and long-term effects of AngioJet and AcoStream mechanical catheter thrombolysis on acute iliofemoral vein thrombosis.

Yang Yaobo Y, Dong Xuan X, Zhao Yilin Y, Chen Sipan S

To compare the short-term and long-term clinical efficacy and safety of AngioJet and AcoStream thrombectomy devices in the treatment of acute iliofemoral venous thrombosis. We conducted a 4-year retrospective case ‒ control study. A total of 243 patients with acute iliofemoral deep vein thrombosis underwent endovascular interventional therapy in our hospital. According to different operation methods, patients were divided into two groups: Group A (AngioJet mechanical thrombectomy system) and Group B (AcoStream mechanical thrombectomy system). The clinical basic data and short-term postoperative efficacy of the two groups were compared. After 36-months of follow-up, the recurrence rate and long-term efficacy of post-thrombotic syndrome were compared between the two groups. The Kaplan-Meier survival method was used to analyze the proportion of Post-Thrombotic Syndrome (PTS). The thrombus aspiration time in the AngioJet group (4.62 ± 0.12 min) was shorter than that in the AcoStream group (5.87 ± 0.09 min) (p = 0.001); the intraoperative blood loss (264.12 ± 5.46 mL) was less than that in the AcoStream group (307.62 ± 4.52 mL) (p < 0.001); the hemoglobin difference (15.57 ± 0.72 g/L) was less than that in the AcoStream group (24.58 ± 0.86 g/L) (p < 0.001); the D - D decrease rate (0.85 ± 0.03 mg/L/D) was faster than that in the AcoStream group (0.75 ± 0.03 mg/L/D) (p = 0.03); the dosage of urokinase (147.39 ± 0.71) million units was more than that in the AcoStream group (125.33 ± 1.01) million. Units (p < 0.001). The swelling reduction rates of the thigh and calf at 24-hours after surgery were (0.61 ± 0.01%) vs. (0.56 ± 0.01%) and (0.63 ± 0.01%) vs. (0.66 ± 0.01%), respectively, with statistically significant differences between the two groups (p < 0.05). The incidence of postoperative hematuria in the AngioJet group (91.9%) was higher than that in the AcoStream group (0.0%) (p < 0.001). After 36-months of follow-up, the thrombus recurrence rate in the AngioJet group (8.9%) was compared with that in the AcoStream group (2.5%) (p < 0.05), and the incidence of postoperative PTS in the two groups was (34.95%) vs. (21.67%) (p = 0.016). Compared with the AcoStream system, the AngioJet system has a higher efficiency of thrombus clearance, but the incidence of hematuria and the recurrence rate are slightly higher. Of course, both have their advantages and disadvantages, and the appropriate surgical method should be selected according to the individual conditions of patients.

PubMedThe Cochrane database of systematic reviews2026-09-15

Strategies to improve recruitment to randomised trials.

Parker Adwoa A, Mongelli Gloria G, Piccolo-Lawrance Camila C, Coleman Elizabeth E et al.

Recruiting participants to randomised controlled trials (RCTs) is challenging. Identifying effective recruitment strategies would benefit health research: poor recruitment leads to underpowered trials, reducing the reliability of findings and increasing the risk of wasted resources, ethical concerns, and trial failure. Evidence to inform recruitment strategies is increasingly generated through Studies Within A Trial (SWATs), which are methodological studies embedded within host RCTs. This is an update of a review last published in 2018. Primary: to quantify the effects of strategies to improve recruitment of participants to RCTs. Secondary: to evaluate recruitment strategies' cost-effectiveness and impact on retention, and the equity, diversity, and inclusion (EDI) characteristics of recruited participants. We used MEDLINE, Embase, and six other databases to identify the studies included in the review. We also sought unpublished recruitment SWATs through social media and targeted email dissemination to trial methodology networks. The latest search date was 16 February 2023. We included randomised SWATs evaluating trial recruitment strategies embedded in healthcare and non-healthcare trials. We excluded quasi-randomised, hypothetical, questionnaire-only, retention-only, or clinician incentive studies. Primary outcome: proportion of eligible participants or centres recruited. cost-effectiveness, retention rates, and EDI characteristics of included participants. We conducted random-effects meta-analysis for strategies evaluated in at least two studies; otherwise, we synthesised results narratively. We reported effects as risk differences (RDs) with 95% confidence intervals (CIs), and assessed between-trial heterogeneity. We used GRADE to assess the certainty of evidence for the primary outcome. We expressed cost-effectiveness as the incremental cost per additional participant recruited in pounds sterling (GBP). We identified 91 eligible studies (53 new to this update), providing 94 comparisons and involving at least 176,747 participants. Eighty-one studies involved strategies aimed at trial participants, while 10 evaluated strategies aimed at recruiters. All were healthcare studies. We found 65 recruitment strategies; 49 were evaluated in a single study. Only five strategies were supported by high-certainty evidence according to GRADE criteria, and we focus on these strategies in the summary below. Open-label trials versus blinded, placebo trials. Open-label trials recruited more participants than blinded trials (RD 10%, 95% CI 8% to 12%; 3 studies, 9004 participants), corresponding to approximately 10 additional participants per 100 approached. The studies involved mostly women in the UK and Estonia. No cost or retention data were reported. Telephone reminder versus no telephone reminder. Telephone reminders to people who did not respond to an initial postal invitation boosted recruitment by 6% (95% CI 3% to 9%; 2 studies, 1450 participants), in trials with low underlying recruitment (we are less certain for trials with over 10% recruitment). The studies involved people with a mean age of 58 years in Canada and Norway. No cost or retention data were reported. Recruitment primer letter versus no letter. Pre-recruitment letters and leaflets designed to encourage participation made little or no difference to recruitment (absolute improvement 1%, 95% CI -1% to 2%; 2 studies, 5376 participants), and were associated with increased costs compared to not sending a primer (incremental cost: GBP 2.08). The studies involved mostly older white people in the UK and Ireland. Multimedia information via a digital link/QR code plus paper participant information leaflet (PIL) versus paper PIL alone. This made little or no difference to recruitment (absolute improvement 0%, 95% CI -1% to 1%; 7 studies, 11,612 participants) and retention (absolute improvement 0%, 95% CI -2% to 3%; 5 studies, 7403 participants), and increased costs compared to not including multimedia information (incremental cost: GBP 0.78). The studies involved people in the UK. Optimised, user-tested PIL versus standard PIL. Optimising participant information leaflets (e.g. through user-testing the leaflet with the target population to shape its content, format, and appearance) made little or no difference to recruitment: absolute improvement was 0% (95% CI 0% to 1%; 6 studies, 27,805 participants). The studies involved people in the UK. Only one study reported EDI data; participants were mostly older women. No cost or retention data were reported. We had moderate-certainty evidence for 13 other strategies; confidence was often reduced because the results came from single studies. Seven strategies involved changes to how potential participants received information; four involved changes to trial conduct; one targeted the recruiter or recruitment site; and one tested non-monetary incentives. We had much less confidence in the other 47 comparisons because the studies had design flaws, were single studies, or had very uncertain results. Costs were reported in only 17 of 91 studies. Strategy impact on retention was reported in 15 studies. All but one study (99%) were from high-income countries. The most reported demographics were age (49 studies), sex (32 studies), gender (27 studies), and education level (16 studies). The evidence on strategies to improve trial recruitment remains broad but lacks depth. Of 65 strategies evaluated, only five were supported by high-certainty evidence. Open-label trial designs and telephone reminders to non-responders increased recruitment, while optimised participant information leaflets, recruitment primer letters, and multimedia information provided alongside a paper participant information leaflet had little or no effect. Reporting of participant characteristics was poor, limiting assessment of equity, diversity, and inclusion across most studies. Evidence is heavily skewed toward high-income countries. Future research must prioritise evaluations in low-to-middle-income settings and consistently report cost, retention, and EDI outcomes. We strongly urge the methodology research community to strengthen the evidence base by prioritising replications of existing strategies over the development and testing of new ones. National Institute for Health and Care Research (Advanced Fellowship, Adwoa Parker, reference:NIHR302256). Health Research Board, Republic of Ireland, Evidence Synthesis Ireland (grant ESI-2021-001) REGISTRATION: This review updates an earlier Cochrane review, which was first published in 2002 and subsequently updated in 2007, 2010, and 2018. Previous versions of the review and their protocols are available at: https://doi.org/10.1002/14651858.MR000013.pub2 https://doi.org/10.1002/14651858.MR000013.pub3 https://doi.org/10.1002/14651858.MR000013.pub4 https://doi.org/10.1002/14651858.MR000013.pub5 https://doi.org/10.1002/14651858.MR000013.pub6.

PubMedCalcified tissue international2026-09-11

SERPINE1/PAI-1 in Skeletal Degeneration: A Proposed Context-Dependent Framework for Bone Remodeling Regulation.

Liu Hang H, Yao Dengbo D, Wang Yu Y, Kong Qingquan Q

SERPINE1 encodes plasminogen activator inhibitor-1 (PAI-1), a key inhibitor of tissue-type and urokinase-type plasminogen activators. Beyond fibrinolysis, PAI-1 participates in extracellular matrix remodeling, cellular senescence, inflammatory amplification, fibrosis-like repair, metabolic stress responses, and bone-cell coupling. These processes are central to osteoporosis, osteoarthritis, and intervertebral disc degeneration, yet the role of SERPINE1/PAI-1 in skeletal tissues is highly context dependent. In osteoporosis, excessive PAI-1 activity is mainly associated with impaired osteogenesis, osteoblast-lineage senescence, defective repair, and bone loss. In osteoarthritis, PAI-1 shows a context-dependent role: persistent elevation may promote chondrocyte senescence and maladaptive matrix remodeling, whereas experimental loss-of-function studies suggest that PAI-1 may protect cartilage in specific settings by restraining excessive plasmin-MMP-mediated degradation. In intervertebral disc degeneration, emerging evidence links SERPINE1 expression and PAI-1 activity to nucleus pulposus cell senescence, fibrosis-like extracellular matrix remodeling, oxidative/metabolic stress, and matrix dysregulation. This review synthesizes current evidence and proposes a testable conceptual framework in which SERPINE1/PAI-1 may function as a stress-responsive remodeling rheostat rather than as a uniformly pathogenic or protective factor. From a translational perspective, SERPINE1/PAI-1 is unlikely to serve as a stand-alone diagnostic biomarker or a target for uniform systemic inhibition. Instead, its clinical value may lie in molecular stratification, identification of disease-stage- and compartment-specific endotypes, and locally targeted modulation of pathogenic downstream programs. Future studies should integrate spatial multi-omics, time-resolved disease models, human cohort validation, and tissue-specific delivery strategies to determine when SERPINE1/PAI-1 is therapeutically actionable in skeletal degeneration.

PubMedAntioxidants & redox signaling2026-09-07

uPAR Amplifies Macrophage Inflammation via NF-κB Pathway to Promote Fibrotic Transition Following Acute Kidney Injury.

Zheng Shengchun S, Chen Yan Y, Liu Jiaona J, Gong Na N et al.

Persistent inflammation is recognized as a major driver of the acute kidney injury (AKI) to chronic kidney disease (CKD) transition, yet upstream macrophage-activation signals remain incompletely understood. Here, we investigated whether the urokinase receptor (uPAR), traditionally linked to matrix remodeling, functions instead as an inflammatory signaling hub that links kidney injury to chronic fibrotic remodeling. In a unilateral renal ischemia-reperfusion injury model, uPAR was induced during the fibrotic phase of postischemic kidney injury. Functional enhancement- and loss-of-function approaches revealed a striking dichotomy: exogenous urokinase (uPA) aggravated renal dysfunction, inflammation, oxidative stress, and fibrosis, whereas uPAR deletion was protective. Mechanistically, uPA/uPAR signaling amplified macrophage inflammatory responses, enhancing M1 polarization, pro-inflammatory cytokine production, reactive oxygen species generation, and NF-κB activation. Molecular docking, mutational modeling, and co-immunoprecipitation analyses revealed a previously underappreciated association between activated uPAR and toll-like receptor 4 (TLR4)-containing complexes. This interaction enhanced myeloid differentiation primary response gene 88-dependent NF-κB signaling and potentiated macrophage inflammatory amplification rather than initiating inflammation independently. NF-κB blockade abolished the pro-inflammatory effects of uPA/uPAR signaling, establishing the functional importance of this pathway. We demonstrate that uPA-activated uPAR engages TLR4-associated signaling to intensify macrophage-driven inflammation, oxidative stress, and fibrotic remodeling. These findings redefine uPAR as a molecular switch governing maladaptive kidney repair and identify the uPA/uPAR-TLR4 signaling interface as a promising therapeutic target. Our findings suggest that the uPA/uPAR-TLR4 axis is involved in regulating the progression from AKI to fibrosis. Targeting this signaling node may represent a novel strategy to interrupt maladaptive repair and prevent CKD following AKI. Antioxid. Redox Signal. 00, 000-000.

PubMedQuantitative imaging in medicine and surgery2026-09-06

Contrast-enhanced ultrasound-guided precision fibrinolysis for refractory loculated chylothorax after lung transplantation: a case report.

Jiang Tingting T, Chen Wuxi W, Peng Zifeng Z, Qiu Shuyi S et al.

Pleural complications remain a major source of morbidity after lung transplantation, with chylothorax posing particular therapeutic challenges. When complicated by fibrinous septation, effective drainage becomes difficult, often necessitating intrapleural fibrinolytic therapy (IPFT). However, in the early post-transplant period, blind fibrinolysis carries substantial risks, including hemorrhage and disruption of fragile bronchial anastomoses or lymphatic vessels. We report a 31-year-old woman with pulmonary lymphangioleiomyomatosis (PLAM) who developed refractory loculated chylothorax 39 days after bilateral lung transplantation. Initial chemical pleurodesis was ineffective and subsequently induced a honeycomb-like, non-communicating pleural effusion that was not amenable to conventional drainage. To balance the need for septation lysis against the risk of bleeding, contrast-enhanced ultrasound (CEUS) was integrated as a real-time guidance tool. CEUS facilitated the precise differentiation between avascular fibrin septa and vascularized pleural tissue, allowing targeted low-dose urokinase injection into isolated locules. The restoration of inter-locule communication was directly visualized, permitting early termination of fibrinolytic exposure. Subsequent drainage and repeat pleurodesis resulted in full lung re-expansion without recurrence. To our knowledge, this is the first case utilizing CEUS to guide precision fibrinolysis in a lung transplant recipient. This case provides a proof-of-concept that CEUS-guided precision fibrinolysis can transform a traditionally blind and high-risk intervention into a controlled, visualization-driven procedure. By enabling targeted intervention and real-time efficacy assessment, this approach offers a safer salvage strategy for high-risk patients.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about urokinase